Abstract C014: Pan-cancer analysis portrays NVL as a diagnostic and prognostic biomarker

Abstract

NVL (also known as NVL2), an AAA+ ATPase, has recently been linked with various cancers. By systematic bioinformatics analyses, here we predict the prospect of NVL as a cancer biomarker. Our pan-cancer analyses reveal that NVL is overexpressed in cancers [GEPIA and UALCAN (TCGA) databases] and the top five cancers with elevated expression (more than twofold) of NVL are Breast Invasive Carcinoma, Testicular Germ Cell Tumors, Cholangiocarcinoma, Diffuse large B cell lymphoma, and Thymoma. NVL is also highly expressed in all stages of most cancers. Additionally, this high expression was found to be correlated to the poor survival of cancer patients (Kaplan-Meier Plotter and OncoDB databases). Since, genetic alteration is one of the major cause of cancer, we investigated mutation and copy number amplification status (cBioPortal and COSMIC databases) of NVL across the cancers. Many potential mutation sites were predicted (cBioPortal and COSMIC databases) and most strikingly, four mutation sites at the ATPase domain of NVL. This signifies that these are the mutations that might have role in carcinogenesis. The copy number amplification study also revealed the high amplification percentage of NVL across different cancers. We further focused on the functional characteristics of the protein NVL across cancers. The protein-protein interaction analyses found the proteins like SKIV2L2, WDR12, WDR74, UTP18, NAT10, TERT, DKC1, GTPBP4, BOP1, TEP1 directly interact with NVL. The top canonical pathways of NVL also indicate that NVL has crucial functions in cancer cell proliferation (DAVID). We, therefore, surmise that NVL could be considered as a potential diagnostic and prognostic marker for multiple cancers and a very promising biomarker and target for cancer.

Citation Format: Mousumi Datta, Dr. Aditi Nayak. Pan-cancer analysis portrays NVL as a diagnostic and prognostic biomarker [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr C014.